ライフサイエンスコーパス: IBS

1 IBS is a functional disorder, while LI is caused by the

2 IBS patients did not differ from HCs with respect to mPF

3 IBS patients underwent small intestinal motility (manome

4 IBS was diagnosed according to the Rome III criteria.

5 IBS was only half as prevalent by Rome IV as by Rome III

6 IBS-C is not a life-threatening condition; however, it h

7 IBS-related symptoms were assessed by using a daily symp

8 IBS-specific CBT has the potential to provide long-term

9 IBS-SSS did not differ between FMT recipients (mean 221

10 iagnoses were NAD = 43 (49%), CD = 17 (19%), IBS = 14 (16%), NSAIDs = 12 (14%) and persistent NSE = 2

11 In total 281 IBS patients (Rome II criteria) were included (74% femal

12 mild (26%), moderate (33%) and severe (41%) IBS-D, classified using the composite scale.

13 f our study is to identify LI patients among IBS patients, so as to set up a correct therapy.

14 3% had at least one hospitalization with an IBS diagnosis, 58% had abdominal ultrasonography, 27% CT

15 pain (P = .016), discomfort (P = .020), and IBS severity (P = .020).

16 SCFA amounts differed in BAD, controls and IBS-D, with significantly more propionate in BAD.

17 and 14 (87%) of the patients with IBS-D and IBS-M, respectively, with decrease of abdominal pain and

18 ome IV criteria for a diagnosis of IBS-D and IBS-M, respectively.

19 y scores; and 2) for patients with IBS-D and IBS-M: resolution of diarrhea.

20 antly reduce abdominal pain, discomfort, and IBS severity.

21 A high degree of overlap with dyspepsia and IBS exists in Nigerian patients with GERD.

22 (GERDQ) while the diagnosis of dyspepsia and IBS was based on the Rome III criteria for the diagnosis

23 nd Rome III questionnaires for dyspepsia and IBS were merged into a composite questionnaire and admin

24 e with IBS alone, and those with both FD and IBS.

25 low LDL levels, high vitamin B(1) levels and IBS before RYGB were independent preoperative predictors

26 ns between these global network measures and IBS symptom severity or GI-specific anxiety but we found

27 e association between the gut microbiome and IBS symptoms has not been well established.

28 LI is often incorrectly diagnosed as IBS.

29 possibly large number of patients labeled as IBS-D or IBS-M may actually simply present functional co

30 stic categories for Bowel Disorders, such as IBS with predominant Diarrhea or Functional Constipation

31 id colon, but not duodenum, differed between IBS patients (n = 17) and HS (n = 20).

32 Fecal bacterial profile differed between IBS subtypes, while the mucosa-associated bacterial prof

33 not find any significant differences between IBS patients and controls in global normalized graph mea

34 brain responses to rectal distention between IBS and healthy controls (HCs) have been demonstrated, p

35 ctional properties of these networks between IBS patients and HCs using graph analysis in two indepen

36 The prevalence of SIBO was similar between IBS patients and HS.

37 but the greatest discrimination was between IBS-D and controls.

38 s with IBS, and in 83% of patients with both IBS and FD.

39 sed patient characteristics and attitudes by IBS-D severity, which was assessed retrospectively using

40 mixed pattern of diarrhea and constipation (IBS-M).

41 itional patients with IBS with Constipation (IBS-C) referred in the same period served as control.

42 able Bowel Syndrome (IBS) with Constipation (IBS-C) should be preliminarily treated for constipation.

43 els included; age, sex, alcohol consumption, IBS diagnosis, family history of gastrointestinal cancer

44 In databases that detect IBS segments using unphased genotypes, approximately 100

45 an erroneous diagnosis of IBS with diarrhea (IBS-D) or IBS with mixed pattern of diarrhea and constip

46 mucosa from patients with IBS with diarrhea (IBS-D; 18 women and 5 men; aged 28-60 years), healthy in

47 ing irritable bowel syndrome with diarrhoea (IBS-D).

48 ta composition among patients with different IBS symptom subtypes.

49 tient records of patients with diagnosed FD, IBS, and/or overlap, who were observed by gastroenterolo

50 (FD), irritable bowel syndrome (IBS), and FD-IBS overlap.

51 FD/IBS was defined by the Rome IV criteria, biliary colic b

52 Of these, 34.9% fulfilled criteria for FD/IBS.

53 e for cholecystectomy fulfil criteria for FD/IBS.

54 my, 40.7% of FD/IBS-group vs. 64.4% of no FD/IBS-group, p < 0.001.

55 Co-existence of FD/IBS may contribute to this unsatisfactory outcome.

56 Primary outcomes were prevalence of FD/IBS, and the difference between resolution of biliary co

57 pain-free after cholecystectomy, 40.7% of FD/IBS-group vs. 64.4% of no FD/IBS-group, p < 0.001.

58 sists in >40%, particularly in those with FD/IBS pre-cholecystectomy.

59 difference between those with and without FD/IBS at baseline (4.9% vs. 8.6%, p = 0.22).

60 ration rates in patients with and without FD/IBS.

61 n-free state in patients with and without FD/IBS.

62 heme (87% of population) through their first IBS hospitalization in 2015.

63 Treatment for PI-IBS followed IBS recommendations, but most physicians also prescribed

64 the 3 countries; ranges were: 4.4%-4.8% for IBS, 7.9%-8.6% for functional constipation, 3.6%-5.3% fo

65 but there is insufficient access to CBT for IBS and uncertainty about whether benefits last in the l

66 Increasing access to CBT for IBS could achieve long-term patient benefit.

67 ed that, at 12 months, both forms of CBT for IBS were significantly more effective than treatment as

68 s and 41.1-90.4% took prescription drugs for IBS-C.

69 a strong decrease after hospitalization for IBS and gastroenterologist visit.

70 rmint oil, and gut-brain neuromodulators for IBS, few of which were judged as being at a low risk of

71 costs to healthcare systems and patient) for IBS-C was euro 1421.7-euro 2487.1.

72 Assessing Cognitive behavioural Therapy for IBS (ACTIB) was a large, randomised, controlled trial of

73 nts referred for psychological treatment for IBS were assessed for eligibility, of whom 354 were rand

74 te inflammation and distinguish pre-IBD from IBS.

75 he fecal microbiota of pre-IBD patients from IBS patients.

76 Patients suffering from IBS frequently suffer from urological symptoms character

77 of failure to achieve improvement in global IBS symptoms at 4-12 weeks, peppermint oil capsules were

78 failure to achieve an improvement in global IBS symptoms at 4-12 weeks, there were no significant di

79 py, in terms of either improvement in global IBS symptoms or improvement in abdominal pain, were incl

80 nd visceral sensitivity parameters, and GSRS-IBS total score and pain domain (rho = 0.40, p < 0.001,

81 GI symptom severity (GSRS-IBS), and anxiety and depression (HAD) as a proxy measur

82 Preoperatively 27/233 participants (12%) had IBS, 2 years after RYGB 61/233 (26%) had IBS-like sympto

83 had IBS, 2 years after RYGB 61/233 (26%) had IBS-like symptoms (p < 0.001).

84 MT in alleviating diarrhoea-predominant IBS (IBS-D).

85 We identified IBS subtype-specific and symptom-related variation in mi

86 In IBS patients, densities were assessed in relation to spe

87 In IBS patients, rectosigmoid mast cell density was higher

88 In IBS, treatments targeting disordered brain-gut axis acti

89 Also, in IBS patients, rectosigmoid eosinophilia was associated w

90 or small intestinal bacterial alterations in IBS.

91 tem for healthcare consumption assessment in IBS points out the repetition of outpatient visits, exam

92 e of the intestinal parasite Blastocystis in IBS patients.

93 Secondary endpoints were changes in IBS symptom scores and quality of life.

94 associated with mPFC GABA+ concentrations in IBS, whereas Glx was unrelated to psychological or gastr

95 The primary outcome was difference in IBS-SSS between the groups at 12 weeks.

96 ota was either decreased or not different in IBS patients compared with controls.

97 sation at rest may be primarily disturbed in IBS.

98 , eosinophils, and TH17 cells were higher in IBS patients as compared to controls.

99 otential to provide long-term improvement in IBS, achievable within a usual clinical setting.

100 4-month follow-up, sustained improvements in IBS were seen in both CBT groups compared with TAU, alth

101 normalities, there was a gradual increase in IBS symptom severity (P < .0001) and somatic symptom sev

102 a novel host-microbial metabolic pathway in IBS with translational potential.

103 for bile acids whose levels can be raised in IBS patients.

104 involved in disturbed emotion regulation in IBS.

105 ysiology measures for GI symptom severity in IBS.

106 ointestinal (GI) tract and to assess SIBO in IBS.

107 Associations between GI symptoms in IBS and individual and combinations of neurophysiologica

108 ly contributing to psychological symptoms in IBS remains unknown.

109 PROs included IBS symptom severity, somatic symptom severity, and dise

110 and moderate to severe disease at inclusion (IBS Symptom Severity Scale score >= 175).

111 ated whether ingestion of FODMAPs can induce IBS-like visceral hypersensitivity mediated by fermentat

112 patients themselves with a focus on managing IBS through different treatment modalities based on seve

113 At 24 months, mean IBS-SSS was 40.5 points (95% CI 15.0 to 66.0; p=0.002) l

114 re IBS-D reported medication use versus mild IBS-D.

115 l infection of rats with Blastocystis mimics IBS symptoms with the establishment of CHS related to mi

116 4 and 7% of patients with mild and moderate IBS-D, respectively (p < 0.05).

117 re IBS-D agreed with the statement: 'When my IBS is bad, I wish I was dead' versus 4 and 7% of patien

118 No IBS-specific biomarker or treatment regimen for PI-IBS c

119 For each observation, IBS draws samples from the simulator model until one mat

120 her these microbes are a product or cause of IBS.

121 acterial composition of the sigmoid colon of IBS patients were linked to symptoms and immune activati

122 was associated with an ultimate diagnosis of IBS (OR 5, p < 0.02).

123 that most patients with initial diagnosis of IBS are, instead, lactose intolerant.

124 may indeed lead to an erroneous diagnosis of IBS with diarrhea (IBS-D) or IBS with mixed pattern of d

125 who met Rome IV criteria for a diagnosis of IBS-D and IBS-M, respectively.

126 We provide theoretical arguments in favor of IBS and an empirical assessment of the method for maximu

127 Despite the heterogeneity of IBS, patients have significant differences in urine and

128 ive of the study was to assess the impact of IBS-D severity on patient burden and patient and healthc

129 Primary endpoints were improvement of IBS symptoms and bloating at 12 weeks (response).

130 Until recently, management of IBS has focused on over-the-counter and prescription med

131 Management of IBS should include an integrated care model in which beh

132 as a central function in the perpetuation of IBS, and for this reason, it can be considered a possibl

133 medication use and a negative perspective of IBS-D.

134 Our results demonstrate the potential of IBS as a practical, robust, and easy to implement method

135 were independent preoperative predictors of IBS-like symptoms at the follow-up visit.

136 w insights into the clinical presentation of IBS.

137 o Rome IV criteria reduces the prevalence of IBS by half, but increases the prevalence of functional

138 med to study the change in the prevalence of IBS-like symptoms 2 years after RYGB and possible preope

139 The prevalence of IBS-like symptoms doubled 2 years after RYGB, and these

140 he co-primary endpoint was overall relief of IBS symptoms, as defined by the European Medicines Agenc

141 The primary outcome was adequate relief of IBS symptoms, with responders defined as patients who re

142 ls, independent of symptom-based subtypes of IBS.

143 iated with severity of at least 1 symptom of IBS.

144 and polyols (FODMAPs) can reduce symptoms of IBS, possibly by reducing microbial fermentation product

145 not associated with more severe symptoms of IBS.

146 been proposed as a strategy for treatment of IBS, but the association between the gut microbiome and

147 difications can be effective in treatment of IBS.

148 onic-release peppermint oil for treatment of IBS.

149 However, participants with new onset IBS-like symptoms had a significant worsening of the men

150 New onset IBS-like symptoms was identified in 45/206 (22%) after R

151 Overlap of GERD with dyspepsia and/or IBS was observed in over 50% of cases.

152 large number of patients labeled as IBS-D or IBS-M may actually simply present functional constipatio

153 us diagnosis of IBS with diarrhea (IBS-D) or IBS with mixed pattern of diarrhea and constipation (IBS

154 by Rome IV and is not unique to either FD or IBS.

155 by SeHCAT testing, were compared with other IBS-D patients, and healthy controls.

156 ite of four variables: worst abdominal pain, IBS symptom frequency, Bristol Stool Form Scale and qual

157 PI-IBS develops in about 10% of patients with infectious en

158 ted that 4 out of 10 patients who develop PI-IBS will have life-long symptoms and described significa

159 probability of their patients developing PI-IBS, if available.

160 ecific biomarker or treatment regimen for PI-IBS currently exists, therefore understanding practice p

161 Treatment for PI-IBS followed IBS recommendations, but most physicians al

162 imated a significant financial burden for PI-IBS patients, ranging from $100-1000 (USD) over the cour

163 em to create guidelines for management of PI-IBS and a developed treatment algorithm based on publish

164 ilable evidence on the pathophysiology of PI-IBS and provide guidance for diagnosis and treatment, ba

165 ize, physician knowledge and treatment of PI-IBS was consistent across respondents.

166 understand the knowledge and treatment of PI-IBS within the physician's current practice.

167 survey respondents (n = 50) were aware of PI-IBS, but less than half discussed this condition as a po

168 plications for practices and treatment of PI-IBS.

169 ls and human studies), and progression of PI-IBS.

170 ways, and genetics), and animal models of PI-IBS.

171 pharmacologic strategies for treatment of PI-IBS.

172 e guidance for diagnosis and treatment of PI-IBS.

173 f postinfection irritable bowel syndrome (PI-IBS) has been substantiated by epidemiology studies cond

174 Post-infectious Irritable Bowel Syndrome (PI-IBS) is a functional bowel disorder which has significan

175 post-infectious Irritable Bowel Syndrome (PI-IBS).

176 pacts to patient's quality of life due to PI-IBS.

177 lgia were strong predictors of postoperative IBS-like symptoms.

178 of FMT in alleviating diarrhoea-predominant IBS (IBS-D).

179 Preoperative IBS and fibromyalgia were strong predictors of postopera

180 In all problems, IBS generally produces lower error in the estimated para

181 ffective than treatment as usual at reducing IBS symptom severity in adults with refractory IBS.

182 is recommended in guidelines for refractory IBS but there is insufficient access to CBT for IBS and

183 trial of patients with treatment-refractory IBS with predominant bloating, FMT relieved symptoms com

184 Participants were adults with refractory IBS (clinically significant symptoms for >=12 months des

185 controlled trial, 558 adults with refractory IBS were randomly allocated to receive either therapist-

186 Patients with refractory IBS, defined as failure of >=3 conventional therapies, w

187 S symptom severity in adults with refractory IBS.

188 wo forms of CBT for patients with refractory IBS.

189 chological disorders, or in those who report IBS-type symptoms.

190 MS) induces bowel dysfunctions that resemble IBS.

191 e another method, inverse binomial sampling (IBS), which can estimate the log-likelihood of an entire

192 me measures were IBS Symptom Severity Score (IBS-SSS) and Work and Social Adjustment Scale (WSAS), as

193 60% (range: 43.1-78.8%) suffered from severe IBS-C.

194 Compared with milder symptoms, severe IBS-D was associated with increased medication use and a

195 ss the economic burden of moderate to severe IBS-C in six European countries (France, Germany, Italy,

196 ct and indirect costs for moderate to severe IBS-C were high with the largest direct cost driver bein

197 ever, 19% of patients classified with severe IBS-D agreed with the statement: 'When my IBS is bad, I

198 icantly more patients classified with severe IBS-D reported medication use versus mild IBS-D.

199 A clinically significant IBS-SSS change (>=50 points) from baseline to 24 months

200 lationships between these cells and specific IBS symptoms and psychologic functioning.

201 sities were assessed in relation to specific IBS symptoms and in relation to self-report anxiety and

202 ed on phenotypic data and identity by state (IBS) distance matrix based on SNP data with the UPGMA cl

203 with genomes that share identical by state (IBS) regions.

204 nematic phase in iron based superconductors (IBSs) has attracted attention with a notion that it may

205 ionnaire, Rome III irritable bowel syndrome (IBS) and constipation questions, and the SF-8 quality of

206 linical spectra of irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) intersect to f

207 Nowadays irritable bowel syndrome (IBS) and lactose intolerance (LI) are two very frequent

208 Irritable bowel syndrome (IBS) and other functional bowel disorders (FBDs) are pre

209 Irritable bowel syndrome (IBS) can be responsible for alteration in quality of lif

210 ovel therapies for irritable bowel syndrome (IBS) continue to be developed, many doctors rely on more

211 in the context of irritable bowel syndrome (IBS) host physiology.

212 with dyspepsia and irritable bowel syndrome (IBS) in Nigeria, a typical African population.

213 Irritable bowel syndrome (IBS) is a common, symptom-based condition that has negat

214 Irritable bowel syndrome (IBS) is a functional disorder of brain-gut interactions.

215 Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder associate

216 Irritable bowel syndrome (IBS) is a heterogeneous disorder, but diagnoses and dete

217 Irritable bowel syndrome (IBS) is characterized by abdominal pain, bloating, and e

218 Irritable bowel syndrome (IBS) is common, affecting 10-20% of the adult population

219 Irritable bowel syndrome (IBS) is prevalent in patients with morbid obesity.

220 uspected of having Irritable Bowel Syndrome (IBS) with Constipation (IBS-C) should be preliminarily t

221 al dyspepsia (FD), irritable bowel syndrome (IBS), and FD-IBS overlap.

222 rders, such as the irritable bowel syndrome (IBS), are associated with elevated levels of intestinal

223 ions are common in irritable bowel syndrome (IBS), but the associations between neurophysiological me

224 ntly used to treat irritable bowel syndrome (IBS), despite a lack of evidence for efficacy from high-

225 hn's disease (CD), Irritable bowel syndrome (IBS), NSAIDs enteritis (NSAIDs), persistent NSE and no s

226 rs and symptoms of irritable bowel syndrome (IBS), or whether these factors have cumulative effects o

227 dyspepsia (FD) and irritable bowel syndrome (IBS), respectively, as defined by Rome IV criteria; and,

228 s of patients with irritable bowel syndrome (IBS), we found that more than half have responses to spe

229 be associated with irritable bowel syndrome (IBS).

230 diseases including irritable bowel syndrome (IBS).

231 been implicated in irritable bowel syndrome (IBS).

232 n in patients with irritable bowel syndrome (IBS).

233 rrhoea-predominant irritable bowel syndrome (IBS-D) is generally based on patient-reported symptoms;

234 The IBS specific bacterial profiles were linked to the colon

235 Patients completed the IBS-specific quality of life questionnaire.

236 ferent from that observed in 15 (93%) of the IBS-C control group.

237 reasingly sought natural solutions for their IBS symptoms.

238 g VOC, SCFA and primary BAs when compared to IBS-D.

239 Several taxa were enriched compared to IBS-D.

240 intolerant subjects and one questionnaire to IBS patients with no LI.

241 hysiological mechanisms that are relevant to IBS.

242 nd healthcare professional attitudes towards IBS.

243 Primary outcome measures were IBS Symptom Severity Score (IBS-SSS) and Work and Social

244 to include LI in the pathologies with which IBS enters into differential diagnosis.

245 ized controlled trials (RCTs) in adults with IBS and other FBDs.

246 ompared prebiotics to placebo in adults with IBS or other FBDs were included.

247 depression have been reported in adults with IBS, relationships between inflammation and psychologic

248 aires regarding the symptoms associated with IBS and LI were administered to the intolerant subjects

249 pathophysiologic alterations associated with IBS have cumulative or independent effects on PROs.

250 ciated bacterial profile was associated with IBS symptom severity and breath tests results at baselin

251 psychologic factors are all associated with IBS symptoms.

252 Eleven participants with IBS preoperatively (41%) did not report such symptoms af

253 Patient with IBS who choose to follow a diet low in fermentable oligo

254 ed a double-blind trial of 190 patients with IBS (according to Rome IV criteria) at 4 hospitals in Th

255 ysis of data from 3 cohorts of patients with IBS (n = 407; 74% female; mean age, 36 +/- 12 years), ba

256 ecal and urine samples from 80 patients with IBS (Rome IV criteria; 16-70 years old) and 65 matched i

257 well as on quality of life, in patients with IBS and are therefore relevant treatment targets.

258 differed significantly between patients with IBS and control individuals, but most discriminatory met

259 specific gut microbes between patients with IBS and controls.

260 inal-release peppermint oil in patients with IBS and explored the effects of targeted ileocolonic-rel

261 f treatment in the majority of patients with IBS and FD and their combination in real clinical practi

262 We enrolled 259 patients with IBS and we compared them to a control group of 108 patie

263 Bacteroides were increased in patients with IBS compared with controls, whereas uncultured Clostridi

264 me profiles could discriminate patients with IBS from control individuals.

265 Patients with IBS had significant differences in network connections b

266 ed as a possible treatment for patients with IBS in primary and secondary care.

267 In a prospective study, 155 patients with IBS received 4 challenges with each of 4 common food com

268 to individual hypnotherapy for patients with IBS referred from primary and secondary care.

269 cy of traditional therapies in patients with IBS to help inform clinical decisions.

270 associated with microbiomes of patients with IBS vs controls.

271 At the HBT, 79.9% (N.=207) of patients with IBS were positive, while in the control group were posit

272 Sixteen additional patients with IBS with Constipation (IBS-C) referred in the same perio

273 t cells in colonic mucosa from patients with IBS with diarrhea (IBS-D; 18 women and 5 men; aged 28-60

274 robiomes of adult or pediatric patients with IBS with microbiomes of healthy individuals (controls).

275 might reduce abdominal pain in patients with IBS with sensitivity to FODMAPs.

276 microbiomes, could distinguish patients with IBS with vs those without BAM.

277 sis can be used to distinguish patients with IBS with vs those without BAM.

278 ry interventions used to treat patients with IBS, a diet low in fermentable oligosaccharides, disacch

279 Patients with IBS, aged 18-65 years, who were referred from primary or

280 of patients with FD, 79.02% of patients with IBS, and in 83% of patients with both IBS and FD.

281 In a CLE analysis of patients with IBS, we found that more than 50% of patients could have

282 In a randomized trial of patients with IBS, we found that neither small-intestinal-release nor

283 by 8 (80%) and 14 (87%) of the patients with IBS-D and IBS-M, respectively, with decrease of abdomina

284 d frequency scores; and 2) for patients with IBS-D and IBS-M: resolution of diarrhea.

285 supernatants from biopsies of patients with IBS-D failed to induce visceral hypersensitivity or incr

286 Colon biopsies from patients with IBS-D had increased levels of PGE2, based on enzyme-link

287 e visceral hypersensitivity in patients with IBS-D.

288 idobacterium were decreased in patients with IBS.

289 d for success in management of patients with IBS.

290 Intracolonic infusions of rats with IBS-D biopsy supernatants generated a 3- to 4-fold incre

291 of more severe symptoms among subjects with IBS and LI than those with IBS and no LI.

292 prevalent in those with FD alone, those with IBS alone, and those with both FD and IBS.

293 ong subjects with IBS and LI than those with IBS and no LI.

294 acid (GABA+) concentrations in 64 women with IBS and 32 age-matched healthy women (HCs) and investiga

295 tients diagnosed in the last five years with IBS-C (Rome III criteria) and moderate to severe disease

296 d TH17 cells, respectively, in 37 youth with IBS and 10 controls.

297 nd with anxiety and depression in youth with IBS.

298 s, eosinophils, and TH17 cells in youth with IBS; and, (2) explore relationships between these cells

299 cal microbiomes of patients with and without IBS to identify biomarkers of this disorder.

300 ears old) and 65 matched individuals without IBS (control individuals), along with anthropometric, me